title: [PREFERE - Study on the rise].
abstract: The PREFERE study, which compares the treatment options for prostate cancer with low and early intermediate risk, has recorded a noticeable upswing in recruitment since mid-2015. Responsible for this are the revised inclusion criteria and the wide support for this study in Germany. The inclusion criteria opened the study to the use of imaging techniques (MRI, C‑Trus / Anna) and the inclusion of all Gleason 3 + 3 = 6 cancers, regardless of tumor extent. In addition, patients can now be included who, for example due to the size of the prostate or existing obstructive micturition disorders, had a contraindication to percutaneous radiotherapy or brachytherapy - these can now be randomized between active surveillance and radical prostatectomy. With the increased recruitment numbers, it seems realistic that the required milestones in recruiting will be achieved.
authors.affiliation: Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Kirrbergerstr., 66421, Homburg/Saar, Deutschland. carsten.ohlmann@uks.eu.
authors.forename: Carsten-H
authors.initials: CH
authors.lastname: Ohlmann
authors.affiliation: Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Kirrbergerstr., 66421, Homburg/Saar, Deutschland.
authors.forename: Michael
authors.initials: M
authors.lastname: Stöckle
authors.affiliation: Klinik für Urologie, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland.
authors.forename: Peter
authors.initials: P
authors.lastname: Albers
authors.affiliation: Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Mainz, Mainz, Deutschland.
authors.forename: Heinz
authors.initials: H
authors.lastname: Schmidberger
authors.affiliation: Institut und Poliklinik für medizinische Psychologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
authors.forename: Martin
authors.initials: M
authors.lastname: Härter
authors.affiliation: Institut für Pathologie, Universitätsklinikum Bonn, Bonn, Deutschland.
authors.forename: Glen
authors.initials: G
authors.lastname: Kristiansen
authors.affiliation: Institut für Klinische Epidemiologie und Angewandte Biometrie, Universität Tübingen, Tübingen, Deutschland.
authors.forename: Peter
authors.initials: P
authors.lastname: Martus
authors.affiliation: Institut für Medizinische Biometrie, Epidemiologie und Informatik, Universität Mainz, Mainz, Deutschland.
authors.forename: Stefan
authors.initials: S
authors.lastname: Wellek
authors.affiliation: Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Kirrbergerstr., 66421, Homburg/Saar, Deutschland.
authors.forename: Roswitha
authors.initials: R
authors.lastname: Bussar-Maatz
authors.affiliation: Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Ulm, Ulm, Deutschland.
authors.forename: Thomas
authors.initials: T
authors.lastname: Wiegel
mesh_terms: D015897:Comorbidity; D003952:Diagnostic Imaging / Q000706:statistics & numerical data; D019317:Evidence-Based Medicine; D005858:Germany / Q000453:epidemiology; D006801:Humans; D038622:Internationality; D008297:Male; D018579:Patient Selection; D011183:Postoperative Complications / Q000175:diagnosis / Q000401:mortality; D011468:Prostatectomy / Q000401:mortality* / Q000706:statistics & numerical data*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D011832:Radiation Injuries / Q000175:diagnosis / Q000401:mortality; D011878:Radiotherapy / Q000401:mortality* / Q000706:statistics & numerical data*; D015996:Survival Rate; D016896:Treatment Outcome
keywords: Brachtherapy; Image-guided biopsy; Patient selection; Prostatectomy; Prostatic neoplasms; Radiotherapy